Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The historical rank and industry rank for Transgene Biotek's Days Payable or its related term are showing as below:
During the past 13 years, Transgene Biotek's highest Days Payable was 129088.33. The lowest was 1187.76. And the median was 4300.26.
BOM:526139's Days Payable is not ranked *
in the Biotechnology industry.
Industry Median: 112.84 * Ranked among companies with meaningful Days Payable only.
Transgene Biotek's Days Payable
stayed the same
from Mar. 2025 (0.00) to Mar. 2026 (0.00).
stayed the same
Transgene Biotek Days Payable Related Terms
Transgene Biotek Days Payable Historical Data
* Premium members only.
The historical data trend for Transgene Biotek's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BOM:526139 vs VRTX, REGN, ALNY: Days Payable Comparison
For the Biotechnology subindustry, Transgene Biotek's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Transgene Biotek Days Payable vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Transgene Biotek's Days Payable distribution charts can be found below:
* The bar in red indicates where Transgene Biotek's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Transgene Biotek's Days Payable for the fiscal year that ended in Mar. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Transgene Biotek (BOM:526139) has a Days Payable of 0.00 as of Mar. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Transgene Biotek and its competitors. Over the past decade, Transgene Biotek's Days Payable has ranged from 1,187.76 to 129,088.33. According to the industry distribution chart, Transgene Biotek ranks #999999 out of 701 companies in the Biotechnology industry.
Is Transgene Biotek's Days Payable too high?
Transgene Biotek's current Days Payable is 0.00. Over the past 10 years, this metric has ranged from a low of 1,187.76 to a high of 129,088.33. Based on the distribution chart, Transgene Biotek ranks #999999 out of 701 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Transgene Biotek has a GF Score™ of 47/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Transgene Biotek's Days Payable compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Transgene Biotek ranks #999999 out of 701 companies for Days Payable. This places Transgene Biotek in the lower half of its industry. The industry median Days Payable is 112.84. Historically, Transgene Biotek's own Days Payable has ranged from 1,187.76 to 129,088.33 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Biotechnology company?
The median Days Payable among Biotechnology companies is 112.84, based on 701 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Transgene Biotek and its competitors. For the Biotechnology industry, the median Days Payable is 112.84 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Transgene Biotek's current Days Payable is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Transgene Biotek stock overvalued right now?
Based on GuruFocus' analysis, Transgene Biotek (BOM:526139) is currently considered Possible Value Trap. The stock's GF Value™ is ₹6.57, compared to a current price of ₹3.07 — trading 53.3% below its estimated fair value. The current Days Payable is 0.00. Transgene Biotek's overall GF Score™ is 47/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Transgene Biotek (BOM:526139), the current Days Payable is 0.00 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Transgene Biotek (BOM:526139) Overvalued in 2026?
Based on GuruFocus' analysis, Transgene Biotek stock appears to be undervalued.
The current stock price of ₹3.07 is trading 53.3% below its estimated GF Value™ of ₹6.57.
GuruFocus considers Transgene Biotek to be Possible Value Trap.
Key valuation signals for BOM:526139:
Days Payable: 0.00
GF Value™: ₹6.57 vs. price of ₹3.07 (53.3% below fair value)
No single metric tells the full story. See the BOM:526139 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Transgene Biotek Ltd is an India-based research and development company. It is engaged in the research and development of molecules and technologies for the production of active pharmaceutical ingredients and other pharmaceutical products. The company is operating only in one segment of Bulk Drugs. Its product portfolio includes TrabiDHA, Tracolimus, and Orlistat. It generates revenue from the sale of goods and services.
47GF Score
Get the complete analysis for BOM:526139
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:526139 has been successfully added to your 
